

## Article

# Further Verticillene Diterpenoids, Eudesmane Sesquiterpe-Noids, and Hydroperoxysteroids from a Taiwanese Soft Coral, *Cespitularia* sp.

Chung-Wei Fu <sup>1</sup>, You-Cheng Lin <sup>2</sup>, Shu-Fen Chiou <sup>1</sup>, Shu-Li Chen <sup>3</sup>, Chi-Chien Lin <sup>4</sup>, Hui-Chun Wang <sup>3</sup>, Chang-Feng Dai <sup>5</sup> and Jyh-Horng Sheu <sup>1,2,3,6,\*</sup>

<sup>1</sup> Department of Marine Biotechnology and Resources, National Sun Yat-sen University, Kaohsiung 804, Taiwan

<sup>2</sup> Doctoral Degree Program in Marine Biotechnology, National Sun Yat-sen University, Kaohsiung 804, Taiwan

<sup>3</sup> Graduate Institute of Natural Products, Kaohsiung Medical University, Kaohsiung 807, Taiwan

<sup>4</sup> Institute of Biomedical Sciences, National Chung Hsing University, Taichung 402, Taiwan

<sup>5</sup> Institute of Oceanography, National Taiwan University, Taipei 106, Taiwan

<sup>6</sup> Department of Medical Research, China Medical University Hospital, China Medical University, Taichung 404, Taiwan

\* Correspondence: sheu@mail.nsysu.edu.tw; Tel.: +886-7-525-2000 (ext. 5030); Fax: +886-7-525-5020

**Abstract:** An investigation of the chemical composition of a Formosan soft coral, *Cespitularia* sp., led to one new verticillene-type diterpenoid, cespitulactam M (**1**); one new eudesmane sesquiterpenoid, cespilamide F (**2**); and three new hydroperoxysteroids (**3–5**) along with twelve known analogous metabolites (**6–17**). In addition, one new derivative, cespitulactam M-6,2'-diacetate (**1a**), was prepared from compound **1**. The structures were determined by detailed spectroscopic analyses, particularly HRESIMS and NMR techniques. Moreover, the in vitro cytotoxicity, anti-inflammatory, and antibacterial activity of **1–17** and **1a** were evaluated.

**Keywords:** *Cespitularia* sp.; verticillene diterpenoids; eudesmane sesquiterpenoids; hydroperoxysteroids

**Citation:** Fu, C.-W.; Lin, Y.-C.; Chiou, S.-F.; Chen, S.-L.; Lin, C.-C.; Wang, H.-C.; Dai, C.-F.; Sheu, J.-H. Further Verticillene Diterpenoids, Eudesmane Sesquiterpe-Noids, and Hydroperoxysteroids from a Taiwanese Soft Coral, *Cespitularia* sp. *Molecules* **2023**, *28*, 1521. <https://doi.org/10.3390/molecules28041521>

Academic Editors: Mohamed L. Ashour, Nawal M. Al Musayeib and Fadia S. Youssef

Received: 17 January 2023

Revised: 3 February 2023

Accepted: 3 February 2023

Published: 4 February 2023




**Copyright:** © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

## 1. Introduction

In the past three decades, a number of studies have shown that the genus of soft coral, *Cespitularia* (a phylum of Xeniidae), elaborates diterpenoids with the verticillene skeleton [1–17] and eudesmane sesquiterpenoids [3,7,17] as major characteristic metabolites, mainly isolated from the species *C. hypotentaculata* and *C. taeniata*, which demonstrated cytotoxic [1–3,6–8,10,11,13], anti-inflammatory [5,16], antiviral [12], and antibacterial [11] activities. In our previous study, we investigated a series of bioactive verticillene diterpenoids as promising compounds for further marine anti-inflammatory drug development [16]. Herein, this continuous chemical investigation of the Formosan *Cespitularia* sp. collected in Green Island led to one new verticillene-type diterpenoid, one new eudesmane sesquiterpenoid, three new hydroperoxysteroids, and twelve known metabolites. Compounds **1–17** were evaluated for anti-inflammatory activity and cytotoxicity against human lung adenocarcinoma (A549), human hepatocellular liver carcinoma (HepG2), and human breast adenocarcinoma (MDA-MB-231) cancer cell lines, and tested for ten species of pathogenic microbes.

## 2. Results and Discussion

The extract of *Cespitularia* sp. was separated by column chromatography and HPLC to afford five new secondary metabolites (**1**–**5**) and twelve related known compounds, which were identified as 7 $\alpha$ -hydroperoxycampesterol (**6**) [18], 7 $\beta$ -hydroperoxycholesterol (**7**) [19], 7 $\alpha$ -hydroperoxycholesterol (**8**) [19], cespitulactam D (**9**) [11], cespitulactam F (**10**) [11], cespitulin S (**11**) [16], cespitularin D (**12**) [1], cespitularin O (**13**) [8], cespitulactone B (**14**) [10], cespiphypotin Q (**15**) [13], atractylenolide II (**16**) [20], and atractylenolide III (**17**) [20] (Figure 1). (Supplementary materials, Figures S1–S68.)




**Figure 1.** Structures of compounds **1**–**17**.

Cespitulactam M (**1**) was obtained as an amorphous solid and displayed HRESIMS ( $m/z$  382.2350 [ $M + Na$ ]<sup>+</sup>, calculated for C<sub>22</sub>H<sub>33</sub>NO<sub>3</sub>Na, 382.2353) consistent with the molecular formula C<sub>22</sub>H<sub>33</sub>NO<sub>3</sub>, implying seven degrees of unsaturation. The IR spectrum revealed the presence of amide (1656 cm<sup>−1</sup>) and hydroxy (3388 cm<sup>−1</sup>) groups. Subsequently, the <sup>1</sup>H NMR and <sup>13</sup>C NMR spectroscopic data (Tables 1 and 2) demonstrated signals of three methyls, eight sp<sup>3</sup> methylenes, one sp<sup>2</sup> methylene, three sp<sup>3</sup> methines, one sp<sup>2</sup> methine, one sp<sup>3</sup>, and five sp<sup>2</sup> quaternary carbons (including a carbonyl carbon appearing at  $\delta_c$  172.5 ppm). The above data accounted for four of the seven degrees of unsaturation, resulting in compound **1** with a tricyclic structure. The COSY spectrum, recorded in


$\text{CDCl}_3$ , showed five proton sequences from H-1 to H-3, H-5 to H-7, H-9 to H-10, H-13 to H-14, and H-2-1' to H-2-2'. Furthermore, key HMBC correlations of H-3 to C-4; H-5 to C-4; H-7 to C-9; H-14 to C-12; H-3-16 to C-1, C-11, and C-15; H-3-17 to C-1, C-11, and C-15; H-2-18 to C-3 and C-5; H-3-19 to C-7, C-8, and C-9 confirmed the connection of the carbon skeleton. Based on the above analysis, the planar structure of **1** was established (Figure 2).

With the planar structure of **1** determined, the relative stereochemistry of the three stereogenic centers, 1*R*\*, 6*S*\*, and 10*R*\*, of **1**, was assigned via the analysis of the NOESY spectrum (Figure 3). It was found that H-1 displayed NOE interactions with H-3-16 and H-3-17, and H-10 also demonstrated NOE interactions with H-3-16, H-3-17, and one proton of H-2-9 ( $\delta_{\text{H}}$  2.74, br d,  $J = 14.4$  Hz). Based on previous studies, all naturally occurring verticillane diterpenoids are assigned H-1 as  $\beta$ -oriented, as shown in verticillene-type derivatives [1–17]. Hence, H-1, one proton of H-2-9 ( $\delta_{\text{H}}$  2.74, br d,  $J = 14.4$  Hz), as well as H-10, would be positioned on the  $\beta$  face. On the other hand, H-6 ( $\delta_{\text{H}}$  4.35, m) exhibited NOE correlations with the other proton of H-2-9 ( $\delta_{\text{H}}$  2.68, dd,  $J = 15.0, 4.2$  Hz), revealing the  $\alpha$ -orientation of proton H-6. On the basis of the NOESY spectral analysis and MM2 force field analysis, the relative structure of cespitulactam **1** was determined. The absolute configuration of **1** was suggested as 1*R*, 6*S*, and 10*R* by the proposed biosynthetic pathway as an intermediate from cespitularin C to cespitulamide C [7].

Furthermore, upon acetylation, compound **1** afforded the diacetate, cespitulactam M-6, 2'-diacetate (**1a**), which exhibited two additional three-proton acetyl singlets at  $\delta_{\text{H}}$  2.01 and  $\delta_{\text{H}}$  2.04. Through the comparison of  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectra of **1** and **1a**, the deshielding of H-2-2' from  $\delta_{\text{H}}$  3.85 to 4.31 and 4.12 suggested the location of an acetyl group at C-2', while the deshielding of H-6 from  $\delta_{\text{H}}$  4.35 to 5.29 also indicated the location of an acetyl group at C-6. In addition, the HRESIMS of **1a** revealed a molecular ion at  $m/z$  466.2565,  $[\text{M} + \text{Na}]^+$  (calculated for  $\text{C}_{22}\text{H}_{33}\text{NO}_3\text{Na}$ , 466.2564).



**Figure 2.** Selected  $^1\text{H}$ - $^1\text{H}$  COSY and HMBC correlations of **1**–**5**.



**Figure 3.** Selected NOE correlations of 1–5.

Cespilamide F (**2**) was obtained as a white powder. The HRESIMS ( $m/z$  300.1572 [ $M + Na$ ] $^+$ , calculated for  $C_{16}H_{23}NO_3Na$ , 300.1570) of **2** established the molecular formula  $C_{16}H_{23}NO_3$ , appropriate for six degrees of unsaturation. Its IR spectrum also revealed the presence of amide ( $1693\text{ cm}^{-1}$ ) and hydroxy ( $3418\text{ cm}^{-1}$ ) groups. The  $^{13}C$  NMR and HSQC spectroscopic data (Tables 1 and 2) illustrated signals of three methyls (including one methoxyl group appearing at  $\delta_H$  3.09 and  $\delta_C$  49.6 ppm), four  $sp^3$  methylenes, one  $sp^2$  methylene, two  $sp^3$  methines, two  $sp^3$ , and four  $sp^2$  quaternary carbons (including one carbonyl carbon appearing at  $\delta_C$  174.3). The above data accounted for three of the six degrees of unsaturation, indicating a tricyclic structure for **2**. From the COSY spectrum measured in  $CDCl_3$ , we established two proton sequences from  $H_{2-1}$  to  $H_{2-3}$  and  $H-5$  to  $H_{2-6}$ . The key HMBC correlations of  $H_{2-6}$  to C-7 and C-8;  $H-9$  to C-7, C-8, and C-10;  $H_{2-13}$  to C-7, C-11, and C-12;  $H_3-14$  to C-1, C-5, C-9, and C-10;  $H_3-15$  to C-3 and C-5; and  $H_3-16$  to C-8 permitted the connection of the carbon skeleton (supplementary materials, S12–S20). Based on the above analysis, the planar structure of **2** was established (Figure 2).

The relative configuration of **2** was determined on the basis of the NOESY experiment and compared with the published compound, taenialactams A, which was isolated from *C. taeniata* in 2009 [3]. Assuming that  $H-5$  ( $\delta_H$  2.28, d,  $J = 12.0$  Hz) possesses an  $\alpha$ -orientation similar to that of taenialactams A, it was found that  $H-5$  ( $\delta_H$  2.28, d,  $J = 12.0$  Hz) demonstrated NOE interactions with one proton of  $H_{2-6}$  ( $\delta_H$  2.54, dd,  $J = 13.2, 3.0$  Hz); therefore,  $H-5$ , and one proton of  $H_{2-6}$  ( $\delta_H$  2.54, dd,  $J = 13.2, 3.0$  Hz) should also be positioned on the  $\alpha$  face. On the contrary, the other one proton of  $H_{2-6}$  ( $\delta_H$  2.16, m) exhibited NOE correlations with  $H_3-14$  ( $\delta_H$  1.00, s) and  $H_3-8-OMe$  ( $\delta_H$  3.09, s). Moreover,  $H-9$  ( $\delta_H$  3.51, s) also showed NOE correlations with  $H_3-14$  ( $\delta_H$  1.00, s) and  $H_3-8-OMe$  ( $\delta_H$  3.09, s), revealing the  $\beta$ -orientation of  $H_{2-6}\beta$  ( $\delta_H$  2.16, m),  $H_3-8-OMe$  ( $\delta_H$  3.09, s),  $H-9$  ( $\delta_H$  3.51, s), and  $H_3-14$  ( $\delta_H$

1.00, s). On the basis of the NOESY spectral analysis and MM2 force field analysis, the relative structure of **2** was determined as 5S\*, 8R\*, 9S\*, and 10S\* (Figure 3).

**Table 1.** <sup>1</sup>H NMR spectroscopic data of compounds 1–5.

Position	1	2	3	4	5
	$\delta_{\text{H}}^{\text{a}}$	$\delta_{\text{H}}^{\text{a}}$	$\delta_{\text{H}}^{\text{a}}$	$\delta_{\text{H}}^{\text{a}}$	$\delta_{\text{H}}^{\text{a}}$
1	1.68 m	2.00 m 1.31 m	1.10 td (12.0, 4.2)	1.84 m 1.14 m	1.85 m 1.06 m
2	2.35 m 2.20 m	1.64 m	1.55 m	1.86 m	1.87 m 1.55 m
3	2.34 m	2.33 m 1.94 m	3.56 quint (4.8)	3.63 quint (5.4)	3.57 m
4			2.40 ddd (13.2, 4.8, 2.4) 2.29 tt (11.4, 2.4)	2.41 ddd (15.0, 5.4, 1.8) 2.33 tt (11.4, 2.4)	2.40 ddd (13.2, 4.8, 2.4) 2.29 tt (9.0, 2.4)
5	2.36 m	2.28 d (12.0)			
6	4.35 m	2.54 dd (13.2, 3.0) 2.16 m	5.58 t (1.8)	5.73 dd (5.4, 1.8)	5.58 t (2.4)
7	5.41 d (8.4) <sup>b</sup>		4.15 dt (8.4, 1.8)	4.17 td (4.8, 1.8)	4.15 dt (9.0, 2.4)
8			1.59 m	1.61 m	1.65 m
9	2.74 br d (14.4) 2.68 dd (14.4, 4.2)	3.51 s	1.09 m	1.41 m	1.09 m
10	4.32 br s				
11			1.55 m 1.46 m	1.48 m	1.56 m
12			2.03 m 1.18 m	1.98 m 1.18 m	2.02 dt (12.6, 3.6) 1.14 m
13	1.57 m	1.85 s			
14	1.69 m	1.00 s	1.10 m	1.47 m	1.10 m
15		4.86 s 4.59 s	1.37 m	1.89 m 1.12 m	1.77 m 1.35 m
16	1.17 s		1.36 m	2.10 m 1.33 m	1.87 m 1.29 m
17	1.40 s		1.23 m	1.31 m	1.17 m
18	4.82 d (6.0)		0.67 s	0.65 s	0.69 s
19	1.43 s		1.04 s	1.00 s	1.05 s
20			1.60 m	1.02 m	1.37 m
21			1.01 d (4.8)	1.04 br s	0.92 d (6.6)
22			0.18 m	0.18 m	1.40 m 0.95 m
23					1.37 m 0.93 m
24			0.24 m	0.24 m	1.18 m
25			1.56 m	1.54 m	1.57 m
26			0.95 d (7.8)	0.96 d (6.6)	0.86 d (7.2)
27			0.85 d (5.4)	0.85 d (7.2)	0.79 d (6.6)
28			0.94 d (7.8)	0.94 d (7.2)	0.78 d (6.6)
29			0.46 dd (9.0, 4.2) −0.12 dd (6.0, 4.2)	0.46 dd (9.6, 4.2) −0.13 dd (6.0, 4.2)	
30			0.90 s	0.91 s	
1'	3.92 ddd (15.0, 7.8, 3.0)				

	3.34 ddd (15.0, 7.8, 3.0)			
2'	3.85 m			
7-OOH		7.45 s	7.59 s	7.48 s
8-OMe	3.09 s			

<sup>a</sup> Spectrum recorded at 600 MHz in CDCl<sub>3</sub>. <sup>b</sup> *J* values (in Hz) in parentheses.

**Table 2.** <sup>13</sup>C NMR spectroscopic data of compounds 1–5.

Position	1	2	3	4	5
	δ <sub>C</sub> <sup>a</sup>	δ <sub>C</sub> <sup>a</sup>	δ <sub>C</sub> <sup>a</sup>	δ <sub>C</sub> <sup>a</sup>	δ <sub>C</sub> <sup>a</sup>
1	43.1 (CH) <sup>b</sup>	34.8 (CH <sub>2</sub> )	36.8 (CH <sub>2</sub> )	36.7 (CH <sub>2</sub> )	36.8 (CH <sub>2</sub> )
2	18.2 (CH <sub>2</sub> )	22.2 (CH <sub>2</sub> )	31.6 (CH <sub>2</sub> )	31.3 (CH <sub>2</sub> )	31.6 (CH <sub>2</sub> )
3	32.5 (CH <sub>2</sub> )	36.1 (CH <sub>2</sub> )	71.3 (CH)	71.4 (CH)	71.3 (CH)
4	146.5 (C)	No detected (C)	41.9 (CH <sub>2</sub> )	42.2 (CH <sub>2</sub> )	41.8 (CH <sub>2</sub> )
5	43.8 (CH <sub>2</sub> )	43.9 (CH)	146.0 (C)	148.9 (C)	146.1 (C)
6	68.3 (CH)	24.3 (CH <sub>2</sub> )	121.5 (CH)	119.9 (CH)	121.5 (CH)
7	134.2 (CH)	151.8 (C)	86.6 (CH)	78.5 (CH)	86.6 (CH)
8	133.4 (C)	93.1 (C)	34.6 (CH)	37.1 (CH)	34.5 (CH)
9	38.5 (CH <sub>2</sub> )	78.7 (CH)	48.7 (CH)	43.5 (CH)	48.7 (CH)
10	62.4 (CH)	40.5 (C)	36.4 (C)	37.4 (C)	36.4 (C)
11	161.3 (C)	130.0 (C)	21.3 (CH <sub>2</sub> )	20.9 (CH <sub>2</sub> )	21.3 (CH <sub>2</sub> )
12	131.6 (C)	174.3 (C)	39.6 (CH <sub>2</sub> )	39.1 (CH <sub>2</sub> )	39.5 (CH <sub>2</sub> )
13	32.0 (CH <sub>2</sub> )	8.1 (CH <sub>3</sub> )	43.3 (C)	42.8 (C)	42.8 (C)
14	24.3 (CH <sub>2</sub> )	16.2 (CH <sub>3</sub> )	55.8 (CH)	48.9 (CH)	55.4 (CH)
15	37.1 (C)	106.6 (CH <sub>2</sub> )	26.2 (CH <sub>2</sub> )	24.7 (CH <sub>2</sub> )	26.0 (CH <sub>2</sub> )
16	35.1 (CH <sub>3</sub> )		28.3 (CH <sub>2</sub> )	28.2 (CH <sub>2</sub> )	28.3 (CH <sub>2</sub> )
17	25.3 (CH <sub>3</sub> )		57.4 (CH)	57.5 (CH)	55.9 (CH)
18	113.8 (CH <sub>2</sub> )		11.9 (CH <sub>3</sub> )	11.3 (CH <sub>3</sub> )	11.8 (CH <sub>3</sub> )
19	17.2 (CH <sub>3</sub> )		18.8 (CH <sub>3</sub> )	18.2 (CH <sub>3</sub> )	18.8 (CH <sub>3</sub> )
20	172.5 (C)		35.2 (CH)	35.4 (CH)	36.1 (CH)
21			21.2 (CH <sub>3</sub> )	21.2 (CH <sub>3</sub> )	18.9 (CH <sub>3</sub> )
22			32.0 (CH)	32.0 (CH)	33.7 (CH <sub>2</sub> )
23			25.8 (C)	25.8 (C)	30.6 (CH <sub>2</sub> )
24			50.8 (CH)	50.8 (CH)	39.1 (CH)
25			32.1 (CH)	32.2 (CH)	31.4 (CH)
26			22.2 (CH <sub>3</sub> )	22.2 (CH <sub>3</sub> )	20.5 (CH <sub>3</sub> )
27			21.5 (CH <sub>3</sub> )	21.5 (CH <sub>3</sub> )	17.6 (CH <sub>3</sub> )
28			15.4 (CH <sub>3</sub> )	15.5 (CH <sub>3</sub> )	15.4 (CH <sub>3</sub> )
29			21.3 (CH <sub>2</sub> )	21.3 (CH <sub>2</sub> )	
30			14.3 (CH <sub>3</sub> )	14.3 (CH <sub>3</sub> )	
1'	44.5 (CH <sub>2</sub> )				
2'	62.2 (CH <sub>2</sub> )				
8-OMe		49.6 (CH <sub>3</sub> )			

<sup>a</sup> Spectrum recorded at 150 MHz in CDCl<sub>3</sub>. <sup>b</sup> Attached protons were deduced by the DEPT experiment.

7β-Hydroperoxygorgosterol (**3**) was also obtained as a white powder. The HRESIMS (*m/z* 481.3651 [M + Na]<sup>+</sup>) of **3** confirmed the molecular formula C<sub>30</sub>H<sub>50</sub>O<sub>3</sub>, implying 6 degrees of unsaturation. The presence of the hydroxy (3380 cm<sup>−1</sup>) group was shown on the IR spectrum. The 1D <sup>13</sup>C NMR and DEPT spectroscopic data (Tables 1 and 2) showed signals of seven methyls, eight sp<sup>3</sup> methylenes, ten sp<sup>3</sup> methines, one sp<sup>2</sup> methine, three sp<sup>3</sup>, and one sp<sup>2</sup> quaternary carbons. The above data accounted for one of the six degrees of unsaturation, indicating a pentacyclic structure for **3** (supplementary materials, S21–S28).

From the COSY spectrum measured in  $\text{CDCl}_3$ , it was possible to establish five proton sequences from H<sub>2</sub>-1 to H<sub>2</sub>-4, H-7 to H<sub>2</sub>-11, H-14 to H-17, H-17 to H-20, H-22 to H<sub>2</sub>-29, and H-24 to H<sub>3</sub>-28. Key HMBC correlations of H<sub>2</sub>-4 to C-5; H-6 to C-4, C-8, and C-10; H-9 to C-5; H<sub>3</sub>-18 to C-12, C-13, C-14, and C-17; H<sub>3</sub>-19 to C-1, C-5, C-9, and C-10; H<sub>3</sub>-21 to C-17, C-20, and C-22; H<sub>3</sub>-28 to C-23; and H<sub>3</sub>-30 to C-22, C-23, C-24, and C-29 permitted the connection of the carbon skeleton. On the basis of the above analysis, the planar structure of **3** was established (Figure 2).

The relative configuration of **3** was elucidated on the basis of the observed key NOE correlations (Figure 3). In particular, the stereo center of C-7 was the most significant result in this compound; thus, it was compared with the reported compounds 7 $\beta$ -hydroperoxycholesterol and its stereoisomer 7 $\alpha$ -hydroperoxycholesterol [19]. In terms of the absolute configuration of the side chain, the 1D NMR spectra of compound **3** were compared with those of gorgosterol [21] and 7-oxogorgosterol [22] from previous research. It turned out that the chemical shifts of compound **3** were similar to that of 7-oxogorgosterol as 20R, 22R, 23R, and 24R. Thus, the absolute configuration of 7 $\beta$ -hydroperoxygorgosterol (**3**) was proposed.

7 $\alpha$ -Hydroperoxygorgosterol (**4**) was isolated as a white powder. The HRESIMS exhibited a  $[\text{M} + \text{Na}]^+$  ion peak at 481.3652  $m/z$ , establishing a molecular formula of  $\text{C}_{30}\text{H}_{50}\text{O}_3$ . By 2D NMR spectroscopy data, including HSQC, COSY, and HMBC (supplementary materials, S29–S36), compound **4** was displayed to possess the same molecular framework as that of **3**. The molecular formula of **3** and **4** indicates that **4** is an isomer of **3**. On the basis of the above references and its NOE correlations, compound **4** was revealed to be the C-7 epimer of **3**, namely 7 $\alpha$ -hydroperoxygorgosterol (**4**).

The HRESIMS of 7 $\beta$ -hydroperoxycampesterol (**5**) showed that it possesses the molecular formula  $\text{C}_{28}\text{H}_{48}\text{O}_3$  ( $m/z$  455.3495  $[\text{M} + \text{Na}]^+$ ). The IR spectrum of **5** showed the absorption of a hydroxy group (3383  $\text{cm}^{-1}$ ). Comparison of the  $^1\text{H}$  and  $^{13}\text{C}$  NMR spectroscopic data of compound **5** with known compound 7 $\alpha$ -hydroperoxycampesterol (**6**) suggested that the planar structure of **5** was the same as 7 $\alpha$ -hydroperoxycampesterol [18].

Owing to the NMR data of **5** and the reported compound 7 $\alpha$ -hydroperoxycampesterol (**6**), this suggests that **5** is an isomer of **6**. Compound **5** was also compared with the known compounds 7 $\beta$ -hydroperoxycholesterol and 7 $\alpha$ -hydroperoxycholesterol in order to define the stereo center C-7 [19]. In terms of the chiral center C-24 on the side chain, the 1D NMR data were compared with those of (24R)-campesterol and (24S)-methylcholesterol [23,24]. Based on the previous literature and NOE correlations, the absolute configuration of **5** was proposed to be 3S, 7R, and 24S.

Compounds **1–16** and **1a** were also evaluated for their cytotoxicity to human lung adenocarcinoma (A549), human hepatocellular carcinoma (HepG2), and human breast adenocarcinoma (MDA-MB-231) cancer cell lines by using the Almar Blue assay [25,26]. The results showed that only 7 $\beta$ -hydroperoxycampesterol (**5**) exhibited cytotoxicity ( $\text{IC}_{50}$  = 15.40, 18.74  $\mu\text{g/mL}$ ) toward the cell lines MDA-MB-231 and A549, compared with the positive control, doxorubicin ( $\text{IC}_{50}$  0.30, 0.15  $\mu\text{g/mL}$ ), respectively, while others did not exhibit cytotoxicity within 20  $\mu\text{g/mL}$ .

Furthermore, the antibacterial activities of **3–7**, **9**, and **12** were tested against the growth of a limited panel of bacteria strains, including *Bacillus subtilis*, *Enterobacter aerogenes*, *Escherichia coli*, *Klebsiella pneumoniae*, *Salmonella enteritidis*, *Salmonella typhimurium*, *Serratia marcescens*, *Shigella sonnei*, *Staphylococcus aureus*, and *Yersinia enterocolitica*. As a result, compound **5** exhibited antibacterial activities against *S. enteritidis* (inhibition zone: 6.0 mm) and *K. pneumoniae* (inhibition zone: 5.0 mm), and compound **9** showed an inhibition zone of 9.0 mm against *K. pneumoniae* at the dosage of 25  $\mu\text{g/disk}$  by the disc diffusion method, compared with the positive control, ampicillin, against *S. enteritidis* (inhibition zone: 10.0 mm) and *K. pneumoniae* (inhibition zone: 5.0 mm) at the same dosage of 25  $\mu\text{g/disk}$ , while others did not show activities to these bacteria strains.

In order to discover bioactive compounds with anti-inflammatory activities by inhibiting TNF- $\alpha$ , PGE<sub>2</sub>, and NO overproduction, **1–10**, **1a**, **14**, and **15** isolated from this extract

were assayed as previously described [16]. At a concentration of 100  $\mu$ M, cespihypotin Q (**15**) could weakly inhibit TNF- $\alpha$  expression and PGE<sub>2</sub> by  $23.6 \pm 2.5\%$  and  $21.2 \pm 0.9\%$ , respectively, relative to the control cells treated with LPS only. In addition, compounds **3**, **4**, **14**, and **15** inhibited NO release by  $33.8 \pm 1.5$ ,  $34.9 \pm 3.9$ ,  $24.8 \pm 1.4$ , and  $35.0 \pm 3.7\%$ , respectively, at a concentration of 100  $\mu$ M for compounds **3**, **14**, and **15**, and at 25  $\mu$ M for compound **4** (supplementary materials, Tables S1–S3).

### 3. Materials and Methods

#### 3.1. General Experimental Procedures

Optical rotations were measured on a JASCO P-1020 digital polarimeter (Jasco Corporation, Tokyo, Japan). IR spectra were recorded on a JASCO P-1020 FT-IR-4100 (Jasco Corporation, Tokyo, Japan) and Nicolet iS5 FT-IR infrared spectrophotometers (Thermo Fisher Scientific Inc., Waltham, Mass., USA). The NMR spectra were recorded on a JEOL ECZ600R FT-NMR (JEOL Ltd., Tokyo, Japan) at 600 and 150 MHz for <sup>1</sup>H and <sup>13</sup>C, respectively, or on a Varian Unity Inova 500 FT-NMR (Varian Inc., Palo Alto, CA, USA) at 500 and 125 MHz for <sup>1</sup>H and <sup>13</sup>C, respectively, or on a Varian 400 FT-NMR at 400 and 100 MHz for <sup>1</sup>H and <sup>13</sup>C, respectively. All NMR experiments were performed at room temperature using CDCl<sub>3</sub> as solvent. ESIMS and HRESIMS data were obtained with a Bruker APEX II mass spectrometer (Bruker, Bremen, Germany). Silica gel (200–400 mesh, Merck, Darmstadt, Germany), reversed-phase silica gel (C18; 230–400 mesh, Merck, Darmstadt, Germany), or Sephadex LH-20 gel (particle size: 18–111  $\mu$ m, GE Healthcare, Chicago, Ill. USA) were used for column chromatography (C.C.). Precoated silica gel plates (Kieselgel 60 F254, 0.2 mm, Merck, Darmstadt, Germany) were also used for analytical thin-layer chromatography (TLC). HPLC was performed on a Hitachi diode array detector L-2455 system and a pump L-2130 system equipped with a Supelco C18 column (5  $\mu$ m, 250  $\times$  21.2 mm; Merck, Darmstadt, Germany).

#### 3.2. Animal Material

The soft coral, *Cespitularia* sp., was collected by hand using SCUBA from the coast of Green Island, Taiwan, in June 2007, at a depth of 10–15 m and stored in a  $-20$  °C freezer until extraction. The soft coral was identified by Professor Chang-Feng Dai, Institute of Oceanography, National Taiwan University. A voucher sample was deposited at the Department of Marine Biotechnology and Resources, National Sun Yat-sen University.

#### 3.3. Extraction and Isolation

The frozen bodies of soft coral *Cespitularia* sp. (880 g, wet weight) were minced and extracted with EtOAc (1 L  $\times$  5) and further extracted exhaustively with MeOH (1 L  $\times$  5). Afterward, the EtOAc extract (4.26 g) was chromatographed by silica gel open column chromatography with solution EtOAc in *n*-hexane (0–100%, gradient) and then substituted for MeOH in EtOAc (0–100%, gradient) to yield 14 fractions. Fraction 6 was further separated via *n*-hexane/EtOAc (6:1–2:1, gradient) to afford seven subfractions (6-1–6-7). In the next step, subfraction 6-7 was purified by reversed-phase HPLC with MeOH/H<sub>2</sub>O (19:1) to afford six hydroperoxysterols; that is, novel chemical structures **3** (2.2 mg), **4** (1.2 mg), **5** (2.6 mg), and known compounds **6** (1.7 mg), **7** (1.8 mg) and **8** (0.7 mg). In terms of known compound **16** (1.9 mg), this compound was isolated from subfraction 6-2 via reversed-phase HPLC with ACN/H<sub>2</sub>O (7:4).

On the other hand, the MeOH extract of this soft coral, *Cespitularia* sp., was partitioned by CH<sub>2</sub>Cl<sub>2</sub> and H<sub>2</sub>O in order to separate the CH<sub>2</sub>Cl<sub>2</sub> soluble fraction for further study. Initially, the CH<sub>2</sub>Cl<sub>2</sub> extract (3.83 g) was chromatographed by silica gel open column chromatography and eluted with EtOAc in *n*-hexane (0–100%, gradient), and then replaced by acetone, MeOH in EtOAc (0–100%, gradient) to yield 17 fractions. Subsequently, fraction 7 was eluted with *n*-hexane/EtOAc (6:1–3:1, gradient) so as to afford five subfractions (7-1–7-5). Afterward, subfraction 7-3 was separated with *n*-hexane/EtOAc



(5:1) and further purified by reversed-phase HPLC with MeOH/H<sub>2</sub>O (2:1) to obtain known compounds **15** (1.7 mg) and **17** (11.6 mg). Similarly, subfraction 7-4 was separated with *n*-hexane/EtOAc (4:1) and eluted via reversed-phase HPLC with ACN/H<sub>2</sub>O (1:1) to obtain known verticillene diterpenoids **11** (1.5 mg) and **14** (1.2 mg). In the next fraction (Fr. 8), this sample was eluted by Sephadex LH-20 column with MeOH, which belongs to size-exclusion chromatography, to yield 6 fractions. Afterward, subfraction 8-5 was purified by RP-HPLC with ACN/H<sub>2</sub>O (1:1) in an effort to obtain a new sesquiterpenoid **2** (1.0 mg) as well as two known verticillene diterpenoids **12** (2.2 mg) and **13** (0.9 mg). Subsequently, a similar method to that used for fraction 8 was used for fractions 14 and 15, except for different solvent systems in RP-HPLC at the last step. To be more specific, known cespitulactam **9** (2.7 mg) and **10** (1.6 mg) were isolated from fraction 14 by reversed-phase HPLC with MeOH/H<sub>2</sub>O (3:2); a new cespitulactam **1** (2.8 mg) was eluted with ACN/H<sub>2</sub>O (1:2) from fraction 15.

*Cespitulactam M (1)*: Amorphous powder;  $[\alpha]^{25}_{\text{D}} -165$  (c 0.05, CHCl<sub>3</sub>); UV (MeOH)  $\lambda_{\text{max}}$  (log  $\epsilon$ ) 241 (3.5) nm; IR (neat)  $\nu_{\text{max}}$  3388, 2921, 2362, 1656 and 1450 cm<sup>-1</sup>; <sup>1</sup>H (600 MHz, CDCl<sub>3</sub>) (see Table 1) and <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) data (see Table 2); HRESIMS  $m/z$  382.2350 [M + Na]<sup>+</sup> (calcd for C<sub>22</sub>H<sub>33</sub>NO<sub>3</sub>Na, 382.2353).

*Cespilamide F (2)*: Amorphous powder;  $[\alpha]^{25}_{\text{D}} +40$  (c 0.04, CHCl<sub>3</sub>); UV (MeOH)  $\lambda_{\text{max}}$  (log  $\epsilon$ ) 230 (3.4) nm; IR (neat)  $\nu_{\text{max}}$  3418, 2924, 2854, 2362, and 1693 cm<sup>-1</sup>; <sup>1</sup>H (600 MHz, CDCl<sub>3</sub>) (see Table 1) and <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) data (see Table 2); HRESIMS  $m/z$  300.1572 [M + Na]<sup>+</sup> (calcd for C<sub>16</sub>H<sub>23</sub>NO<sub>3</sub>Na, 300.1570).

*7β-Hydroperoxygorgosterol (3)*: White solid;  $[\alpha]^{25}_{\text{D}} +12$  (c 0.11, CHCl<sub>3</sub>); UV (MeOH)  $\lambda_{\text{max}}$  (log  $\epsilon$ ) 213 (3.5) nm; IR (neat)  $\nu_{\text{max}}$  3380, 2933, 2850, 2362, and 1459 cm<sup>-1</sup>; <sup>1</sup>H (600 MHz, CDCl<sub>3</sub>) (see Table 1) and <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) data (see Table 2); HRESIMS  $m/z$  481.3651 [M + Na]<sup>+</sup> (calculated for C<sub>30</sub>H<sub>50</sub>O<sub>3</sub>Na, 481.3652).

*7α-Hydroperoxygorgosterol (4)*: White solid;  $[\alpha]^{25}_{\text{D}} -93$  (c 0.07, CHCl<sub>3</sub>); UV (MeOH)  $\lambda_{\text{max}}$  (log  $\epsilon$ ) 213 (3.5) nm; IR (neat)  $\nu_{\text{max}}$  3384, 2933, 2871, 2360, and 1457 cm<sup>-1</sup>; <sup>1</sup>H (600 MHz, CDCl<sub>3</sub>) (see Table 1) and <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) data (see Table 2); HRESIMS  $m/z$  481.3652 [M + Na]<sup>+</sup> (calculated for C<sub>30</sub>H<sub>50</sub>O<sub>3</sub>Na, 481.3652).

*7β-Hydroperoxycampesterol (5)*: White solid;  $[\alpha]^{25}_{\text{D}} +17$  (c 0.12, CHCl<sub>3</sub>); UV (MeOH)  $\lambda_{\text{max}}$  (log  $\epsilon$ ) 239 (3.5) and 215 (3.5) nm; IR (neat)  $\nu_{\text{max}}$  3383, 2933, 2868, 2360, and 1457 cm<sup>-1</sup>; <sup>1</sup>H (600 MHz, CDCl<sub>3</sub>) (see Table 1) and <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) data (see Table 2); HRESIMS  $m/z$  455.3495 [M + Na]<sup>+</sup> (calculated for C<sub>28</sub>H<sub>48</sub>O<sub>3</sub>Na, 455.3496).

*7α-Hydroperoxycampesterol (6)*: White solid;  $[\alpha]^{25}_{\text{D}} -134$  (c 0.05, CHCl<sub>3</sub>); <sup>1</sup>H (400 MHz, CDCl<sub>3</sub>) and <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) data (supplementary materials, Figures S45 and S46); ESIMS  $m/z$  455 [M + Na]<sup>+</sup>, molecular formula C<sub>28</sub>H<sub>48</sub>O<sub>3</sub>.

*7β-Hydroperoxycholesterol (7)*: White solid;  $[\alpha]^{25}_{\text{D}} +43$  (c 0.05, CHCl<sub>3</sub>); <sup>1</sup>H (400 MHz, CDCl<sub>3</sub>) and <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) data (supplementary materials, Figures S47 and S48); ESIMS  $m/z$  441 [M + Na]<sup>+</sup>, molecular formula C<sub>27</sub>H<sub>46</sub>O<sub>3</sub>.

*7α-Hydroperoxycholesterol (8)*: White solid;  $[\alpha]^{25}_{\text{D}} -97$  (c 0.03, CHCl<sub>3</sub>); <sup>1</sup>H (400 MHz, CDCl<sub>3</sub>) and <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) data (supplementary materials, Figures S49 and S50); ESIMS  $m/z$  441 [M + Na]<sup>+</sup>, molecular formula C<sub>27</sub>H<sub>46</sub>O<sub>3</sub>.

*Cespitulactam D (9)*: White solid;  $[\alpha]^{25}_{\text{D}} -86$  (c 0.05, CHCl<sub>3</sub>); <sup>1</sup>H (400 MHz, CDCl<sub>3</sub>) and <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) data (supplementary materials, Figures S51 and S52); ESIMS  $m/z$  338 [M + Na]<sup>+</sup>, molecular formula C<sub>20</sub>H<sub>29</sub>NO<sub>2</sub>.

*Cespitulactam F (10)*: White solid;  $[\alpha]^{25}_{\text{D}} -168$  (c 0.02, CHCl<sub>3</sub>); <sup>1</sup>H (400 MHz, CDCl<sub>3</sub>) and <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) data (supplementary materials, Figures S53, S54); ESIMS  $m/z$  354 [M + Na]<sup>+</sup>, molecular formula C<sub>20</sub>H<sub>29</sub>NO<sub>3</sub>.

*Cespitulin S (11)*: White solid;  $[\alpha]^{25}_{\text{D}} +13$  (c 0.06, CHCl<sub>3</sub>); <sup>1</sup>H (600 MHz, CDCl<sub>3</sub>) and <sup>13</sup>C NMR (150 MHz, CDCl<sub>3</sub>) data (supplementary materials, Figures S55 and S56); ESIMS  $m/z$  387 [M + Na]<sup>+</sup>, molecular formula C<sub>21</sub>H<sub>32</sub>O<sub>5</sub>.

*Cespitularin D (12)*: White solid;  $[\alpha]^{25}_{\text{D}} -67$  (c 0.03, CHCl<sub>3</sub>); <sup>1</sup>H (400 MHz, CDCl<sub>3</sub>) and <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) data (supplementary materials, Figures S57 and S58); ESIMS  $m/z$  355 [M + Na]<sup>+</sup>, molecular formula C<sub>20</sub>H<sub>28</sub>O<sub>4</sub>.

*Cespitularin O* (**13**): White solid;  $[\alpha]^{25}_D$   $-25$  ( $c$  0.02,  $\text{CH}_2\text{Cl}_2$ );  $^1\text{H}$  (400 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ) data (supplementary materials, Figures S59 and S60); ESIMS  $m/z$  339  $[\text{M} + \text{Na}]^+$ , molecular formula  $\text{C}_{20}\text{H}_{28}\text{O}_3$ .

*Cespitulactone B* (**14**): White solid;  $[\alpha]^{25}_D$   $-148$  ( $c$  0.03,  $\text{CHCl}_3$ );  $^1\text{H}$  (400 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ) data (supplementary materials, Figures S61 and S62); ESIMS  $m/z$  369  $[\text{M} + \text{Na}]^+$ , molecular formula  $\text{C}_{21}\text{H}_{30}\text{O}_4$ .

*Cespilhypotin Q* (**15**): White solid;  $[\alpha]^{25}_D$   $-36$  ( $c$  0.06,  $\text{CH}_2\text{Cl}_2$ );  $^1\text{H}$  (400 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ) data (supplementary materials, Figures S63 and S64); ESIMS  $m/z$  385  $[\text{M} + \text{Na}]^+$ .

*Atractulenolide II* (**16**): White solid;  $[\alpha]^{25}_D$   $+190$  ( $c$  0.08,  $\text{CHCl}_3$ );  $^1\text{H}$  (400 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ) data (supplementary materials, Figures S65 and S66); ESIMS  $m/z$  255  $[\text{M} + \text{Na}]^+$ .

*Atractulenolide III* (**17**): White solid;  $[\alpha]^{25}_D$   $+244$  ( $c$  0.41,  $\text{CHCl}_3$ );  $^1\text{H}$  (400 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ ) data (supplementary materials, Figures S67 and S68); ESIMS  $m/z$  271  $[\text{M} + \text{Na}]^+$ .

*Cespitulactam M-6, 2'-diacetate* (**1a**): *Cespitulactam M* (**1**) (1.2 mg) in pyridine was mixed with  $\text{Ac}_2\text{O}$ , and the mixture was stirred at room temperature for 24 h. After evaporation of excess reagent, the acetyl derivative of **1a** (1.0 mg) was yielded as a white solid.  $[\alpha]^{25}_D$   $-100$  ( $c$  0.02,  $\text{CHCl}_3$ );  $^1\text{H}$  (600 MHz,  $\text{CDCl}_3$ ) and  $^{13}\text{C}$  NMR (150 MHz,  $\text{CDCl}_3$ ) data (supplementary materials, Figures S9–S11); HRESIMS  $m/z$  466.2565  $[\text{M} + \text{Na}]^+$  (calcd for  $\text{C}_{22}\text{H}_{33}\text{NO}_3\text{Na}$ , 466.2564).

### 3.4. Cytotoxicity Assay

Cell lines were purchased from the American Type Culture Collection (ATCC). Cytotoxicity of compounds **1–17** and **1a** were assayed using the Almar Blue assay [25,26]. Doxorubicin, employed as positive control, showed cytotoxic activity toward HepG2, MDA-MB231, and A549 cell lines with  $\text{IC}_{50}$  = 0.37, 0.30, and 0.15  $\mu\text{g/mL}$ , respectively.

### 3.5. In Vitro Antibacterial Assay

The antibacterial assay of compounds **1–17** and **1a** was evaluated against *B. subtilis* (ATCC 6051), *E. aerogenes* (ATCC 13048), *E. coli* (ATCC 25922), *K. pneumoniae* (ATCC 10031), *S. enteritidis* (ATCC 13076), *S. typhimurium* (ATCC 14028), *S. marcescens* (ATCC 25419), *S. sonnei* (ATCC 11060), *S. aureus* (ATCC 9144), and *Y. enterocolitica* (ATCC 23715), by the procedures described previously [27].

### 3.6. In Vitro Anti-Inflammatory Assay

#### 3.6.1. Measurement of Cytokine Production by Dendritic Cells (DCs)

The experiment for measuring cytokine was tested by enzyme-link immunosorbent assay (ELISA) from the previously reported method [28,29]. The DCs were manipulated with lipopolysaccharide (LPS, 100 ng/mL) from *Escherichia coli* 055:B5 and the following treatment with the isolated compounds for 24 h. The optical density of the production of  $\text{TNF-}\alpha$  was measured at 450 nm using the ELISA reader.

#### 3.6.2. Measurement of Nitric Oxide (NO) Production by DCs

DC cells were seeded in 24-well plates at a density of  $1 \times 10^6$  cells/mL. DCs were treated with each compound for 1 h and then stimulated with 100 ng/mL LPS for 24 h. The nitrite concentration in the medium was measured as an indicator of NO production through the Griess reaction. Briefly, 100  $\mu\text{L}$  of cell culture supernatant was reacted with 100  $\mu\text{L}$  of Griess reagent (1:1 mixture of 2% sulfanilamide and 0.2% *N*-(1-naphthyl)ethylenediamine dihydrochloride in water) in 96-well plate at room temperature for 10 min, and absorbance at 540 nm was recorded using sandwich ELISA assays [28,29].

#### 3.6.3. Statistical Analysis

The results are expressed as the mean  $\pm$  SEM, and comparisons were made using one-way ANOVA by Tukey's post hoc test (GraphPad Prism 5.0, GraphPad Software, San Diego, CA, USA). A probability value of 0.05 or less was considered significant. The software Sigma Plot was used for the statistical analysis.

#### 4. Conclusions

In conclusion, a new nitrogen-containing verticillene diterpenoid, cespitulactam M (1); one new eudesmane sesquiterpenoid, cespilamide F (2); and three new hydroperoxy-steroids (3–5) along with twelve known analogous metabolites (6–17) were isolated from a Formosan soft coral, *Cespitularia* sp. Subsequently, one new acetyl-derivative, cespitulactam M-6,2'-diacetate (1a), was prepared from compound 1, and its bioactivities were evaluated. Furthermore, hydroperoxysteroids (3–8) were discovered in the genus of *Cespitularia* for the first time; in particular, 7 $\beta$ -hydroperoxygorgosterol (3) and 7 $\alpha$ -hydroperoxygorgosterol (4) showed anti-inflammatory activities. Moreover, 7 $\beta$ -hydroperoxycampessterol (5) exhibited weak cytotoxicity and antibacterial activities. In this study, soft coral *Cespitularia* sp., with abundant natural product resources, resulted in a wide variety of chemical structures as well as diverse bioactivities for further research.

**Supplementary Materials:** The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/molecules28041521/s1>, Figures S1–S68: ESIMS and NMR spectra of compounds 1–17, Tables S1–S3: the results of cytotoxic, antibacterial, and anti-inflammatory activities.

**Author Contributions:** J.-H.S. conceptualized and guided the experiment; C.-W.F. and Y.-C.L. purified, analyzed, and elucidated the structures of compounds; J.-H.S. and C.-W.F. prepared the manuscript; C.-W.F., S.-F.C., S.-L.C., C.-C.L., and H.-C.W. performed data acquisition and bioassays; C.-F.D. identified the species of soft coral. All authors have read and agreed to the published version of the manuscript.

**Funding:** This study was funded by the Ministry of Science and Technology (MOST 107-2320-B-110-001-MY3, and MOST 111-2320-B-110-010) of Taiwan.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Data from the present study are available in the article and Supplementary Materials.

**Conflicts of Interest:** The authors declare no conflicts of interest.

**Sample Availability:** Samples of the compounds are not available from the authors.

#### References

1. Duh, C.-Y.; El-Gamal, A.A.H.; Wang, S.-K.; Dai, C.-F. Novel Terpenoids from the Formosan Soft Coral *Cespitularia hypotentaculata*. *J. Nat. Prod.* **2002**, *65*, 1429–1433. <https://doi.org/10.1021/np020077w>.
2. Shen, Y.-C.; Lin, Y.-S.; Kuo, Y.-H.; Cheng, Y.-B. Cespitulactams A, B, and C, Three New Nitrogen-Containing Diterpenes from *Cespitularia taeniata* May. *Tetrahedron Lett.* **2005**, *46*, 7893–7897. <https://doi.org/10.1016/j.tetlet.2005.09.105>.
3. Cheng, Y.-B.; Chen, C.-Y.; Kuo, Y.-H.; Shen, Y.-C. New Nitrogen-Containing Sesquiterpenoids from the Taiwanese Soft Coral *Cespitularia taeniata* May. *Chem. Biodivers.* **2009**, *6*, 1266–1272. <https://doi.org/10.1002/cbdv.200800195>.
4. Cheng, S.-Y.; Lin, E.-H.; Wen, Z.-H.; Chiang, M.Y.-N.; Duh, C.-Y. Two New Verticillane-Type Diterpenoids from the Formosan Soft Coral *Cespitularia hypotentaculata*. *Chem. Pharm. Bull.* **2010**, *58*, 848–851. <https://doi.org/10.1248/cpb.58.848>.
5. Chang, J.-Y.; Fazary, A.-E.; Lin, Y.-C.; Hwang, T.-L.; Shen, Y.-C. New Verticillane Diterpenoids from *Cespitularia taeniata*. *Chem. Biodivers.* **2012**, *9*, 654–661. <https://doi.org/10.1002/cbdv.201100122>.
6. Lin, Y.-C.; Wang, S.-S.; Chen, C.-H.; Kuo, Y.-H.; Shen, Y.-C. Cespitulones A and B, Cytotoxic Diterpenoids of a New Structure Class from the Soft Coral *Cespitularia taeniata*. *Mar. Drugs* **2014**, *12*, 3477–3486. <https://doi.org/10.3390/md12063477>.
7. Wang, S.-S.; Cheng, Y.-B.; Lin, Y.-C.; Liaw, C.-C.; Chang, J.-Y.; Kuo, Y.-H.; Shen, Y.-C. Nitrogen-Containing Diterpenoids, Sesquiterpenoids, and Nor-Diterpenoids from *Cespitularia taeniata*. *Mar. Drugs* **2015**, *13*, 5796–5814. <https://doi.org/10.3390/md13095796>.
8. Duh, C.-Y.; Li, C.-H.; Wang, S.-K.; Dai, C.-F. Diterpenoids, Norditerpenoids, and Secosteroids from the Formosan Soft Coral *Cespitularia hypotentaculata*. *J. Nat. Prod.* **2006**, *69*, 1188–1192. <https://doi.org/10.1021/np0505465>.

9. Shen, Y.-C.; Lin, J.-J.; Wu, Y.-R.; Chang, J.-Y.; Duh, C.-Y.; Lo, K.-L. New Norditerpenoids from *Cespitularia hypotentaculata*. *Tetrahedron Lett.* **2006**, *47*, 6651–6655. <https://doi.org/10.1016/j.tetlet.2006.06.178>.
10. Shen, Y.-C.; Ho, C.-J.; Kuo, Y.-H.; Lin, Y.-S. Cespitulactones A and B, New Diterpenoids from *Cespitularia taeniata*. *Bioorganic Med. Chem. Lett.* **2006**, *16*, 2369–2372. <https://doi.org/10.1016/j.bmcl.2006.01.118>.
11. Shen, Y.-C.; Cheng, Y.-B.; Kobayashi, J.; Kubota, T.; Takahashi, Y.; Mikami, Y.; Ito, J.; Lin, Y.-S. Nitrogen-Containing Verticillene Diterpenoids from the Taiwanese Soft Coral *Cespitularia taeniata*. *J. Nat. Prod.* **2007**, *70*, 1961–1965. <https://doi.org/10.1021/np078011u>.
12. Shen, Y.-C.; Wu, Y.-R.; Lin, J.-J.; Lo, K.-L.; Kuo, Y.-C.; Khalil, A.-T. Eight New Diterpenoids from Soft Coral *Cespitularia hypotentaculata*. *Tetrahedron* **2007**, *63*, 10914–10920. <https://doi.org/10.1016/j.tet.2007.08.068>.
13. Shen, Y.-C.; Lo, K.-L.; Kuo, Y.-H.; Kuo, Y.-C.; Chen, C.-H.; Khalil, A.-T. Cespiphypotins Q–V, Verticillene Diterpenoids from *Cespitularia hypotentaculata*. *J. Nat. Prod.* **2008**, *71*, 1993–1997. <https://doi.org/10.1021/np8005327>.
14. Cheng, Y.-B.; Lo, K.-L.; Chen, C.-Y.; Khalil, A.-T.; Shen, Y.-C. New Verticillane-Type Diterpenoids from the Taiwanese Soft Coral *Cespitularia hypotentaculata*. *Helv. Chim. Acta* **2008**, *91*, 2308–2315.
15. Chang, J.-Y.; Abd El-Razek, M.H.; Shen, Y.-C. Verticillane and Norverticillane Diterpenoids from the Formosan Soft Coral *Cespitularia hypotentaculata*. *Helv. Chim. Acta* **2009**, *92*, 2146–2154. <https://doi.org/10.1002/hlca.200900224>.
16. Lin, Y.-C.; Lin, C.-C.; Chu, Y.-C.; Fu, C.-W.; Sheu, J.-H. Bioactive Diterpenes, Norditerpenes, and Sesquiterpenes from a Formosan Soft Coral *Cespitularia* sp. *Pharmaceuticals* **2021**, *14*, 1252. <https://doi.org/10.3390/ph14121252>.
17. Lin, Y.-C.; Abd El-Razek, M.H.; Shen, Y.-C. Verticillane-Type Diterpenoids and an Eudesmanolide-Type Sesquiterpene from the Formosan Soft Coral *Cespitularia hypotentaculata*. *Helv. Chim. Acta* **2010**, *93*, 1238. <https://doi.org/10.1002/hlca.200900196>.
18. Pinto, F.C.L.; Almeida, J.G.; Silveira, E.R.; Costa, A.M.; Guimarães, L.A.; Wilke, D.V.; Costa-Lotufo, L.V.; Torres, M.C.M.; Pessoa, O.D.L. Steroids from the Brazilian Zoanthids *Palythoa caribaeorum* and *Palythoa variabilis*. *J. Braz. Chem. Soc.* **2017**, *28*, 485–491. <https://doi.org/10.21577/0103-5053.20160323>.
19. Sung, P.-J.; Lin, M.-R.; Chen, J.-J.; Lin, S.-F.; Wu, Y.-C.; Hwang, T.-L.; Fang, L.-S. Hydroperoxysterols from the Tunicate *Eudistoma* sp. *Chem. Pharm. Bull.* **2007**, *55*, 666–668. <https://doi.org/10.1248/cpb.55.666>.
20. Duan, J.-A.; Wang, L.; Qian, S.; Su, S.; Tang, Y. A New Cytotoxic Prenylated Dihydrobenzofuran Derivative and Other Chemical Constituents from the Rhizomes of *Atractylodes lancea* DC. *Arch. Pharm. Res.* **2008**, *31*, 965–969. <https://doi.org/10.1007/s12272-001-1252-z>.
21. Thanh, N.V.; Ngoc, N.T.; Anh, H.L.T.; Thung, D.C.; Thao, D.T.; Cuong, N.X.; Nam, N.H.; Kiem, P.V.; Minh, C.V. Steroid Constituents from the Soft Coral *Sinularia microspiculata*. *J. Asian Nat. Prod. Res.* **2016**, *18*, 938–944. <https://doi.org/10.1080/10286020.2016.1173676>.
22. Al-Lihaibi, S.S.; Abdel-Lateff, A.; Alarif, W.M.; Alorfi, H.S.; Nogata, Y.; Okino, T. Environmentally Friendly Antifouling Metabolites from Red Sea Organisms. *J. Chem.* **2019**, *2019*, 3278394. <https://doi.org/10.1155/2019/3278394>.
23. Fan, F.; Li, G.-Q.; Li, Z.-J.; Zhang, J.; Yuan, E.; Wu, L.; Ma, G.-Q.; Bae, Y.-S. Steroidal Compounds from Roots of *Cinnamomum camphora*. *Chem. Nat. Compd.* **2020**, *56*, 177–179. <https://doi.org/10.1007/s10600-020-02979-3>.
24. Rahelivao, M.P.; Lübken, T.; Gruner, M.; Kataeva, O.; Ralambondrahety, R.; Andriamanantoanina, H.; Checinski, M.P.; Bauer, I.; Knölker, H.J. Isolation and Structure Elucidation of Natural Products of Three Soft Corals and a Sponge from the Coast of Madagascar. *Org. Biomol. Chem.* **2017**, *15*, 2593–2608. <https://doi.org/10.1039/c7ob00191f>.
25. Nakayama, G.R.; Caton, M.C.; Nova, M.P.; Parandoosh, Z. Assessment of the Alamar Blue Assay for Cellular Growth and Viability *In Vitro*. *J. Immunol. Methods* **1997**, *204*, 205–208. [https://doi.org/10.1016/s0022-1759\(97\)00043-4](https://doi.org/10.1016/s0022-1759(97)00043-4).
26. O'Brien, J.; Wilson, I.; Orton, T.; Pognan, F. Investigation of the Alamar Blue (Resazurin) Fluorescent Dye for the Assessment of Mammalian Cell Cytotoxicity. *Eur. J. Biochem.* **2000**, *267*, 5421–5426. <https://doi.org/10.1046/j.1432-1327.2000.01606.x>.
27. Lin, Y.-C.; Chao, C.-H.; Fu, C.-W.; Chiou, S.-F.; Huang, T.-Y.; Yang, Y.-J.; Wu, S.-H.; Chen, S.-L.; Wang, H.-C.; Yu, M.-C.; et al. Computationally Assisted Structure Elucidation of New 2-Guanidinoethanesulfonyl Sesquiterpenoid Alkaloids: Agelasidines G–I from the Marine Sponge *Agelas nakamurai*. *Tetrahedron* **2022**, *126*, 133077. <https://doi.org/10.1016/j.tet.2022.133077>.
28. Lin, M.-K.; Yu, Y.-L.; Chen, K.-C.; Chang, W.-T.; Lee, M.-S.; Yang, M.-J.; Cheng, H.-C.; Liu, C.-H.; Chen, D.-C.; Chu, C.-L. Kaempferol from *Semen cuscudae* Attenuates the Immune Function of Dendritic Cells. *Immunobiology* **2011**, *216*, 1103–1109. <https://doi.org/10.1016/j.imbio.2011.05.002>.
29. Lai, K.-H.; You, W.-J.; Lin, C.-C.; El-Shazly, M.; Liao, Z.-J.; Su, J.-H. Anti-Inflammatory Cembranoids from the Soft Coral *Lobophytum crassum*. *Mar. Drugs* **2017**, *15*, 69–78. <https://doi.org/10.3390/md15100327>.

**Disclaimer/Publisher's Note:** The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.